Nitrothiazole Derivative Selective Antibacterial Action
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Clostridium difficile infections, such as metronidazole, are ineffective and have adverse effects on intestinal probiotics, leading to relapse and complications.
Innovation Solution
A nitazoxanide derivative with a specific alkyl group structure is developed, which forms the basis of an antibacterial drug that inhibits Clostridium difficile growth with minimal impact on intestinal probiotics, preventing and treating infections and complications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibiotics such as metronidazole are used to treat Clostridium difficile infections, then the treatment can address the infection, but they have adverse effects on intestinal probiotics and lead to relapse
Solution Approach 1:
The patent modifies the chemical structure of nitazoxanide by introducing different alkyl groups (methyl, ethyl, propyl, butyl groups) at specific positions of the molecule. This structural parameter change enhances the drug's selectivity for Clostridium difficile while reducing its impact on beneficial intestinal bacteria, thereby resolving the contradiction between treatment effectiveness and harm to probiotics
Solution Approach 2:
The invention introduces specific alkyl substitutions at particular positions (R1, R2, R3, R4) of the nitazoxanide core structure. These localized structural modifications create regions of increased selectivity that allow the drug to target Clostridium difficile specifically while sparing other intestinal microorganisms, thus addressing the harmful effects on probiotics
2Reliability
If nitazoxanide is used to treat Clostridium difficile enteritis, then it shows effectiveness especially when metronidazole is ineffective, but its mechanism is not clear and it affects intestinal microbiota
Solution Approach 1:
The patent systematically varies the alkyl chain length and branching at different positions of the nitazoxanide molecule. This parameter optimization enhances the drug's ability to selectively inhibit Clostridium difficile through improved binding affinity to the PFO enzyme, while the modified structure reduces non-specific effects on other intestinal microbiota
Solution Approach 2:
The invention creates a series of derivatives with gradually increasing alkyl chain lengths (methyl to butyl groups), allowing for dynamic optimization of the drug's selectivity profile. This systematic variation enables fine-tuning of the drug's interaction with Clostridium difficile PFO while minimizing off-target effects on beneficial bacteria
3Productivity
If antibiotics are used to treat Clostridium difficile infections, then the bacterial growth can be inhibited, but relapse occurs and complications arise
Solution Approach 1:
The patent optimizes the alkyl substitution parameters to achieve potent and sustained inhibition of Clostridium difficile. The enhanced binding affinity of the derivatives to the bacterial PFO enzyme ensures complete eradication of the pathogen, preventing relapse caused by surviving bacteria or spores that would otherwise recur after standard antibiotic treatment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The derivative effectively inhibits Clostridium difficile with lower toxic side effects and reduced relapse rates compared to existing antibiotics, demonstrating improved selectivity and efficacy in treating Clostridium difficile infections and their complications.
Implementation Method 1
it is considered to be related to the inhibition of enzyme-dependent electron transfer reaction of pyruvate and ferredoxin oxidoreductase (PFO), which is important for anaerobic energy metabolism
Data Source
AI summary
A compound represented by formula (I) is effective in inhibiting the growth of Clostridium difficile. Compared with nitazoxanide and other antibiotics, the compound also has significantly less influence on intestinal probiotics and lower toxic side effects while significantly inhibiting the activity of Clostridium difficile, and the disease is not easy to relapse after the drug is stopped.